Advertisement

National point prevalence of Clostridium difficile in US health care facility inpatients, 2008

Published:March 12, 2009DOI:https://doi.org/10.1016/j.ajic.2009.01.001

      Background

      Recent published estimates of Clostridium difficile infection (CDI) incidence have been based on small numbers of hospitals or national hospital discharge data. These data suggest that CDI incidence is increasing.

      Methods

      We conducted a point prevalence survey of C difficile in inpatients at US health care facilities. The survey was developed, received Institutional Review Board approval, and was then distributed to all Association for Professionals in Infection Control and Epidemiology, Inc (APIC) members. They were asked to complete the survey on 1 day between May 7 and August 29, 2008, reporting the number of inpatients with CDI or colonization and facility-specific information.

      Results

      Personnel at 648 hospitals completed the survey; this represents approximately 12.5% of all US acute care facilities. All but 3 states and the District of Columbia were represented (mean, 14 facilities per state; range, 2-43). Eighty-two percent reported that their CDI rate had not decreased in the past 3 years. Respondents reported 1443 C difficile-colonized/infected patients among 110,550 inpatients; the overall C difficile prevalence rate was 13.1 per 1000 inpatients (94.4% infection). Detailed data were provided on 1062 (73.6%) patients. Of these, 55.5% were female, 69.2% were >60 years of age, 67.6% had selected comorbid conditions, 79% had received antimicrobials within 30 days, and 94.4% were detected by enzyme immunoassay. The majority of patients (54.4%) were diagnosed ≤48 hours of hospitalization, but 35% had been admitted to a long-term care facility within 30 days, and 47% had been hospitalized within 90 days; 73% met Centers for Disease Control and Prevention criteria for health care-associated CDI. Most facilities (>90%) used contact isolation for CDI patients. Bleach was used for environmental disinfection more commonly during CDI outbreaks than during nonoutbreak periods.

      Conclusion

      Our survey documents a higher C difficile prevalence rate than previous estimates using different methodologies. The majority of inpatient CDI appears to be health care associated. Given that not all patients with diarrhea are tested for CDI and that most facilities use enzyme immunoassays with limited sensitivity to detect C difficile, these are minimum estimates of the US health care facility C difficile burden.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hall I.C.
        • O'Toole E.
        Intestinal flora in newborn infants: with a description of a new pathogenic anaerobe, Bacillus difficilis.
        Am J Dis Child. 1935; 49: 390-402
        • Bartlett J.G.
        Clinical practice: antibiotic-associated diarrhea.
        N Eng J Med. 2002; 346: 334-339
        • Archibald L.K.
        • Banerjee S.N.
        • Jarvis W.R.
        Secular trends in hospital-acquired Clostridium difficile disease in the United States.
        J Infect Dis. 2004; 189: 1585-1589
        • McDonald L.C.
        • Owings M.
        • Jernigan J.B.
        Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.
        Emerg Infect Dis. 2006; 12: 409-415
      1. Elixhauser A, Jhung M. Clostridium difficile-associated disease in US hospitals, 1993-2005. HCUP statistical brief No. 50, April 2008. US Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs.sb50.pdf. Accessed February 16, 2009.

        • McDonald L.C.
        • Kilgore G.E.
        • Thompson A.
        • Owens Jr., R.C.
        • Kazakova S.V.
        • Sambol S.P.
        • et al.
        An epidemic, toxin gene-variant strain of Clostridium difficile.
        N Eng J Med. 2005; 353: 2433-2441
        • Muto C.A.
        • Pokrywka M.
        • Shutt K.
        • Mendelsohn A.B.
        • Nouri K.
        • Posey K.
        • et al.
        A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.
        Infect Control Hosp Epidemiol. 2005; 26: 273-280
        • Kelly C.P.
        • LaMont J.T.
        Clostridium difficile—more difficult than ever.
        N Eng J Med. 2008; 359: 1932-1940
        • McDonald L.C.
        • Coignard C.
        • Dubberke E.
        • Song X.
        • Horan T.
        • Kutty P.K.
        • et al.
        Recommendations for surveillance of Clostridium difficile-associated disease.
        Infect Control Hosp Epidemiol. 2007; 28: 140-145
        • American Hospital Association
        AHA hospital statistics 2008.
        AHA, Chicago, IL2007
        • Dubberke E.R.
        • Reske K.A.
        • McDonald L.C.
        • Fraser V.J.
        ICD-9 codes and surveillance for Clostridium difficile-associated disease.
        Emerg Infect Dis. 2006; 12: 1576-1579
        • McFarland L.V.
        • Clarridge J.E.
        • Beneda H.W.
        • Raugi G.J.
        Fluoroquinolone use and risk factors for Clostridium difficile-associated disease in a Veterans Administration health care system.
        Clin Infect Dis. 2007; 45: 1141-1151
        • Planche T.
        • Aghaizu A.
        • Holliman R.
        • Riley P.
        • Poloniechi J.
        • Breathnach A.
        • et al.
        Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review.
        Lancet Infect Dis. 2008; 8: 777-784
        • Vanpoucke H.
        • De Baere T.
        • Clauys G.
        • Vaneechoutte M.
        • Verschraegen G.
        Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens.
        Clin Microbiol Infect. 2001; 7: 55-64
        • Delmee M.
        • Van Broeck J.
        • Simon A.
        • Janssens M.
        • Avesani V.
        Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture.
        J Med Microbiol. 2005; 54: 187-191
        • Nuila F.
        • Cadle R.M.
        • Logan N.
        • Musher D.M.
        Members of the infectious disease section of the Michael DeBakey VA Medical Center. Antibiotic stewardship and Clostridium difficile-associated disease.
        Infect Control Hosp Epidemiol. 2008; 29: 1096-1097
      2. Sehulster L, Chinn RYW. Centers for Disease Control and Prevention Healthcare Infection Control Practices (HICPAC) guidelines for environmental infection control in health-care facilities, 2003. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Enviro_guide_03.pdf. Accessed February 16, 2009.

      3. Boyce JM, Pittet D. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for hand hygiene in healthcare settings, 2002. Available at: http://www.cdc.gov/nciDOD/dhqp/gl_handhygiene.html. Accessed February 16, 2009

        • Kyne L.
        • Hamel M.B.
        • Polavaram R.
        • Kelly C.P.
        Health care cost and mortality associated with nosocomial diarrhea due to Clostridium difficile.
        Clin Infect Dis. 2002; 34: 346-353
        • Dubberke E.R.
        • Wertheimer A.I.
        Review of current literature on the economic burden of Clostridium difficile infection.
        Infect Control Hosp Epidemiol. 2009; 30: 57-66
        • Dubberke E.R.
        • Butler A.M.
        • Reske K.A.
        • Agniel D.
        • Olsen M.A.
        • D'Angelo G.
        • et al.
        Attributable outcomes in Clostridium difficile-associated disease in nonsurgical patients.
        Emerg Infect Dis. 2008; 14: 1031-1038
        • Dubberke E.R.
        • Reske K.A.
        • Olsen M.A.
        • McDonald L.C.
        • Fraser V.J.
        Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients.
        Clin Infect Dis. 2008; 46: 497-504
        • Lawrence S.J.
        • Puzniak L.A.
        • Shadel B.N.
        • Gillespie K.N.
        • Kollef M.H.
        • Mundy L.M.
        Clostridium difficile in intensive care unit: epidemiology, costs, and colonization pressure.
        Infect Control Hosp Epidemiol. 2007; 28: 123-130
        • Vonberg R.P.
        • Reichardt C.
        • Behnke M.
        • Schwab F.
        • Zindler S.
        • Gastmeier P.
        Costs of nosocomial Clostridium difficile-associated diarrhoea.
        J Hosp Infect. 2008; 70: 15-20
        • Zilberberg M.D.
        Clostridium difficile-related hospitalizations among US adults, 2006.
        Emerg Infect Dis. 2009; 15: 122-124
        • Kenneally C.
        • Rosini J.M.
        • Skrupky L.P.
        • Doherty J.A.
        • Hollands J.M.
        • Martinez E.
        • et al.
        Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting.
        Chest. 2007; 132: 418-424
        • Dubberke E.R.
        • Gerding D.N.
        • Classen D.
        • Arias K.M.
        • Podgorny K.
        • Anderson D.J.
        • et al.
        Strategies to prevent Clostridium difficile infections in acute care hospitals.
        Infect Control Hosp Epidemiology. 2008; 29: S81-S92